Rxsight, Inc. Stock Price, News & Analysis

RxSight (RXST) reported strong Q1 2025 financial results with revenue of $37.9 million, up 28% year-over-year. The company sold 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedures, and added 73 Light Delivery Devices (LDD™s), expanding the installed base to 1,044 units. Gross profit reached $28.3 million (74.8% margin), while net loss improved to $(8.2) million or $(0.20) per share. The company maintained its 2025 guidance, projecting revenue of $160-175 million and operating expenses of $150-160 million. Management highlighted strong customer enthusiasm and strategic growth opportunities through service center expansion and international approvals.

RxSight, a specialized ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Bank of America Healthcare Conference in Las Vegas.

The company's management team is set to deliver their presentation on Wednesday, May 14, 2025, at 3:40 PM Pacific Time (6:40 PM Eastern Time). Investors and interested parties can access both the live presentation and archived recording through the company's investor relations website at https://investors.rxsight.com/.

This presentation at a major healthcare conference represents an opportunity for RxSight to showcase their innovations in customized vision solutions for cataract surgery patients. The company's participation in this significant industry event demonstrates their commitment to engaging with the investment community and sharing their business developments.

RxSight Inc (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has scheduled its Q1 2025 financial results announcement for May 7, 2025 after market close.

The company will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss the results. Investors can participate by dialing (800) 715-9871 or (646) 307-1963 with conference code 8740296. A live audio-only webcast will be available through the investor relations website, with a recording accessible afterward.

RxSight (NASDAQ: RXST) announced preliminary Q1 2025 revenue of $37.9 million, showing 28% year-over-year growth but a 6% decrease from Q4 2024. The company reported selling 27,579 Light Adjustable Lenses, a 36% increase from Q1 2024, and 73 Light Delivery Devices, expanding the installed base to 1,044 LDDs (43% growth year-over-year).

Due to headwinds in the premium IOL market and broader economy, RxSight revised its 2025 guidance downward. The new full-year revenue guidance is $160.0-175.0 million (down from $185.0-197.0 million), representing 14-25% growth. Operating expenses are now projected at $150.0-160.0 million, reduced from $165.0-170.0 million, including non-cash stock-based compensation of $27.0-30.0 million.

RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on post-cataract surgery customized vision solutions, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's management will engage in a fireside chat scheduled for April 8, 2025, at 9:45 AM PT / 12:45 PM ET. Interested parties can access both the live presentation and archived recording through RxSight's investor relations website at https://investors.rxsight.com/.

RxSight (RXST) reported strong Q4 and full-year 2024 financial results. Q4 revenue reached $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The LDD installed base expanded to 971 units.

Full-year 2024 revenue grew 57% to $139.9 million, with 98,055 LALs and 305 LDDs sold. Gross profit margin improved to 71.6% in Q4 2024, up from 61.8% in Q4 2023. The company reported a reduced Q4 net loss of $(5.9) million compared to $(9.2) million in Q4 2023.

For 2025, RxSight reaffirmed guidance projecting revenue of $185.0-197.0 million (32-41% growth), gross margin of 71-73%, and operating expenses of $165.0-170.0 million.

RxSight (RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has announced it will release its fourth quarter 2024 financial results on February 25, 2025, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone at (800) 715-9871 or (646) 307-1963 using conference code 7159871, or listen to the webcast through the company's investor relations website. A recording will be available after the call.

RxSight (NASDAQ: RXST) reported preliminary Q4 2024 revenue of $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The company's installed base reached 971 LDDs, a 46% increase from Q4 2023.

Full-year 2024 revenue is expected at $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company now serves approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region's premium IOL market.

For 2025, RxSight projects revenue between $185.0-197.0 million (32-41% growth), with gross profit margins of 71-73% and operating expenses of $165.0-170.0 million. Cash position as of December 31, 2024, was $237.2 million.

RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.rxsight.com.